Tempus Soars: Q3 2026 Results Showcase Dazzling Growth and Strategic Partnerships
Tempus, a leading healthcare technology company, has released its Q3 2026 financial results, showcasing an impressive quarter of growth and strategic partnerships. The company's diagnostics business delivered $303.5 million in revenue, an increase of 20% year-over-year, driven by oncology revenues, which grew 28%, with volume growth of 32%. This is some of the strongest unit volume growth the company has seen in years.
Tempus' data and apps business also experienced significant growth, with revenues increasing 33% year-over-year. The company's Insights segment, a leading provider of data licensing services, grew 29%, further solidifying Tempus' position as a leader in the healthcare technology space.
The company's strategic partnerships have been a major driver of its success, with recent agreements including a collaboration with Bristol Myers Squibb (BMS) to license BMS oncology data and models for up to $137.5 million over a five-year term. This is one of Tempus' largest strategic collaborations to date.
Tempus also announced a multi-year collaboration with Moderna and Merck to support the commercialization of their novel individualized neoantigen therapy (INT). The company's acquisition of Personalis has cleared regulatory review, and the two companies will continue to work together on oncology diagnostics and MRD testing.
Eric Lefkofsky, founder and CEO of Tempus, stated that the company's results reinforce its durable model, which combines best-in-class diagnostic platforms with data and AI offerings. This approach has helped drive consistent quarter-after-quarter performance and distinguishes the company from its competitors.
The future looks bright for Tempus, as it continues to leverage its innovative platform to deliver exceptional results and forge new partnerships. With a growing market share in oncology diagnostics and a strong pipeline of strategic collaborations, Tempus is well-positioned for continued growth and success.
